Two treatments, two different hip problems

These two treatments are often mentioned in the same breath, but they rarely suit the same hip. Whether one or the other is appropriate is not really a matter of preference — it is a question of what the hip joint actually looks like on imaging and clinical assessment.

ChondroFiller injection is designed for diffuse, advanced cartilage loss: the Kellgren-Lawrence Grade III or IV hip where wear is spread across the joint surface rather than concentrated in one area. In that setting, there is no intact cartilage border left to anchor a surgical repair. The injection works with what remains, providing a viscoelastic scaffold over degenerated surfaces rather than attempting to restore a discrete lesion.

Hip arthroscopy, by contrast, is built for a structurally different problem — a focal, contained cartilage defect surrounded by healthy tissue, or a mechanical issue such as femoroacetabular impingement, a labral tear, or acetabular dysplasia. These are conditions where the joint retains enough structural integrity to support a surgical repair or correction.

Neither treatment is routinely funded by the NHS for cartilage indications, so both are pursued privately. The sections below examine what each involves in practice.

What ChondroFiller injection involves

Delivered at an outpatient clinic rather than an operating theatre, the ChondroFiller injection requires no general anaesthetic, no surgical incision, and no hospital admission. A typical appointment at Lincolnshire Hip begins with a review of existing hip imaging. Professor Paul Lee — a hip specialist who runs clinics locally in Grantham and Sleaford — maps the cartilage defect before ultrasound guidance is used to position the needle precisely within the hip joint.

That guidance is not optional. The collagen solution gels irreversibly within three to five minutes of entering the joint environment, bonding directly to degenerated articular surfaces. Ultrasound placement achieves 100% accurate intra-articular delivery compared with 72% for landmark-guided techniques, so positioning is critical to the treatment performing as intended.

ChondroFiller is a CE-marked Class III medical device — an acellular Type I collagen scaffold manufactured by Meidrix Biomedicals in Germany. Once in situ, it provides an immediate viscoelastic cushion over worn hip joint surfaces while acting simultaneously as a chemotactic matrix: the patient's own progenitor cells migrate into the scaffold over the following weeks, mature into chondrocytes, and begin building new tissue. The scaffold is fully resorbed and replaced by native tissue within one to two years. Post-treatment MRI in treated patients has confirmed measurable structural changes, including reduction in bone marrow oedema and visible joint-space widening. In hip-specific studies, clinical outcomes measured on the modified Harris Hip Score have improved by approximately 30 points over 12 months.

Because the mechanism is additive — coating what remains rather than removing tissue — there is no upper age limit and 'bone on bone' advanced hip OA does not exclude a patient. Most people leave the clinic the same day.

What private hip arthroscopy involves

Hip arthroscopy takes place in an operating theatre under general or spinal anaesthesia. The surgeon inserts a small camera and instruments through two or three portal incisions, working in a dry joint field — a key difference from the fluid environment used for ultrasound-guided injection. This controlled, pressurised setting allows direct visualisation of articular surfaces, the acetabular labrum, and bony anatomy.

The procedure is the appropriate route when the hip retains enough structural integrity for a surgical repair to take hold. Its primary indication is a focal, contained cartilage defect at ICRS Grade III/IV with viable surrounding cartilage borders — the kind of lesion where the surgeon has healthy tissue to work with. Through the arthroscope, a range of cartilage techniques can be performed: debridement alone (chondroplasty, for symptom management), marrow-stimulation with microfracture, or more advanced single-stage procedures such as AMIC or OATS for defects requiring biological restoration. Microfracture has a historical role but current evidence points to fibrocartilage breakdown within two to three years and potential subchondral bone damage that can compromise later repair options; most hip specialists now favour augmented or graft-based approaches where the defect size and patient profile support them.

Hip arthroscopy is also the procedure of choice for femoroacetabular impingement, symptomatic labral tears, acetabular dysplasia, and hypermobility. FAI correction carries a preventive benefit beyond immediate pain relief: cam and pincer morphology, if untreated, accelerates cartilage loss and is a recognised pathway to premature hip osteoarthritis.

Private hip arthroscopy in the UK is priced approximately £7,000–£15,000 depending on provider and procedure complexity — figures from Nuffield Health, Spire, and Circle Health Group sit within this range. Where cartilage repair implants or additional procedures are added, costs rise accordingly. Most patients are discharged the same day or after one night; jogging is typically permitted around four months post-surgery, with a full return to activity taking five to seven months.

Cost and what each price actually covers

The figures for both pathways need unpacking before they can be compared meaningfully. ChondroFiller injection is priced at £6,500–£9,500 in the UK — a figure that is all-inclusive: consultation, ultrasound guidance, the collagen scaffold device, IV antibiotic cover, and a six-week follow-up. There is no separate facility fee, no anaesthesia charge, and no inpatient admission to factor in.

Fully-inclusive hip arthroscopy packages tend to be higher than the headline range established above. The hip attracts approximately a 30% uplift over knee-based cartilage surgery pricing at specialist centres, placing all-in costs at around £12,700 or more once pre-operative assessment, theatre fees, anaesthetic, implants, and follow-up are bundled together. Where labral repair or additional implant work is added, costs can rise considerably further — hip labrum repair in the UK can start from £16,000.

The headline cost gap between the two pathways sits at roughly £4,000–£6,000 in favour of ChondroFiller injection, and that figure does not capture indirect costs. For Lincolnshire patients, private hip arthroscopy generally means travelling to London or a larger regional centre, adding accommodation and transport expenses that appear nowhere in a provider's published price. Exact arthroscopy pricing at Lincolnshire-specific facilities was not available in the evidence reviewed; the ranges above are drawn from national provider data.

Neither pathway is currently NHS-funded for cartilage indications. Patients either self-fund or, where applicable, seek coverage through health insurance — though written pre-authorisation is always required before treatment begins, and approval is not guaranteed.

Recovery: what to expect from each pathway

Practical recovery differs meaningfully between the two pathways, and it is worth mapping this clearly before committing to either.

ChondroFiller injection is an outpatient procedure: patients leave the clinic the same day. For the first four to six weeks, a 'Protect' phase applies — modified activity, reduced weight-bearing as directed, and avoidance of high-impact loading while the collagen scaffold bonds and early cell migration begins. A progressive strengthening programme follows over the next four to six weeks, reintroducing muscle load and low-impact movement. Full functional benefit typically emerges over a three-to-six-month window as the scaffold integrates and fibrocartilage forms.

Hip arthroscopy requires hospital admission — usually day-case, occasionally overnight — plus surgical wound care, crutches for between two and six weeks depending on what was carried out, and a structured physiotherapy programme. Jogging is typically permitted around four months post-surgery, with full return to strenuous activity taking five to seven months. General anaesthesia adds its own short-term burden: post-anaesthetic fatigue, a driving restriction of at least 24–48 hours, and the small but real physiological recovery associated with any operative procedure under sedation.

For both pathways, pre-treatment hip muscle conditioning — where time and symptoms allow — can support a smoother post-procedure rehabilitation. This applies equally to injection and surgical patients.

One honest caveat: long-term comparative outcome data beyond five years, drawn from randomised controlled trials directly comparing ChondroFiller injection with hip arthroscopy in matched hip populations, is not currently available. Patients making a decision between the two should factor this into the conversation with their consultant.

Getting assessed in Lincolnshire

For patients across Lincolnshire, the practical starting point is the same regardless of which pathway ends up being appropriate. Professor Paul Lee at Lincolnshire Hip works with both ChondroFiller injection and private hip arthroscopy, so the structural assessment drives the treatment recommendation rather than a patient arriving having already pre-selected a procedure.

Consultations and ChondroFiller injection delivery are available locally in Grantham and Sleaford — no travel to London is required for the injection pathway. Where private hip arthroscopy is the right clinical choice, Professor Lee's surgical access at Weymouth Street Hospital in London means patients do not need to source a separate provider or navigate an unfamiliar system.

Before booking a paid consultation, two no-cost steps are available at lincolnshirehip.com: a free 15-minute discovery call and a two-minute online suitability assessment that maps the hip across clinical criteria and produces a personal result to bring to an appointment. No GP referral is needed at any stage.